PTC Therapeutics Q2 net income $83.5M, raises FY product revenue guidance to $850-950M

PTC THERAPEUTICS, INC.

Q2 total revenue $361M (product $239M) includes $50M Novartis milestone; net income $83.5M vs net loss $64.8M YoY.
FY 2026 product revenue guidance raised to $850-950M (from $750-850M); total revenue guidance raised to $1.18-1.28B.
Sephience Q2 revenue $151M (+21% QoQ); 1,647 patients on therapy; Translarna $42.2M, Emflaza $24.6M, Evrysdi royalty $71.1M.
Issued $550M senior convertible notes due 2031 at 0% coupon, 40% conversion premium; repurchased majority of 1.5% notes due 2026. Cash $2.23B.
Pipeline: PTC303 (MSH3) targeting Huntington's, clinic entry 2027; PTC612 (NLRP3) Phase 1 initiated; vatiquinone PROVE-FA study Q3 2026; votoplam PIVOT-HD 24-month results showed 52% disease slowing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.